Scientific, Technical Research and Project Management Support Services for USAMRIID
Defense Health Agency · DEFENSE HEALTH AGENCY
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation HT9426-26-C-E008 in this department, oldest first.
- May 20, 2026 · this noticeAward NoticeCHENEGA SERVICES & FEDERAL SOLUTIONS, LLC · $72.4M
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Note the winner and the end of the period of performance for the recompete.
- Follow the agency to see the next notice for this work.
What the notice says
Chenega Services & Federal Solutions, LLC recieved a Cost Plus Fixed Fee award as a result of a competitive, 8(a) requirement to provide Scientific, Technical Research and Project Management Support Services in support of USAMRIID.
Who won similar work
4 award notices on SAM.gov in the last 24 months. Matched by: Same agency (Defense Health Agency), same NAICS 541714.
Single-winner award sizes (4): middle half $233K to $4.4M, median $1.1M; range $110K to $11.5M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| CHENEGA PROFESSIONAL & TECHNICAL SERVICES LLC | 1 | $11.5M | Sep 29, 2025 |
| MAPP BIOPHARMACEUTICAL, INC. | 1 | $2.0M | Jun 4, 2025 |
| ILLUMINA, INC. · $ILMN · $4.5B | 1 | $273K | May 30, 2026 |
| POTOMAC AFFINITY PROTEINS, LLC | 1 | $110K | Jul 9, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $ILMN reported $4.5B revenue in FY2025. The median single-winner award in these 4 past awards, $1.1M, is under 0.1% of that. 10-K
One award's total value against one year of revenue; many awards are paid over several years.
- May 30, 2026ILLUMINA, INC.$273KIllumina Urinary Pathogen Identification (ID)/Antimicrobial Resistance (AMR) Enrichment Kit (UPIP), (1) Respiratory Pathogen ID/AMR Enrichment Kit Set A,
- Sep 29, 2025CHENEGA PROFESSIONAL & TECHNICAL SERVICES LLC$11.5MScientific and Technical Research Support Services
- Jul 9, 2025POTOMAC AFFINITY PROTEINS, LLC$110KUsing Protease Cascades to Detect Protein Targets
- Jun 4, 2025MAPP BIOPHARMACEUTICAL, INC.$2.0Mhuman-derived monoclonal antibodies (mAbs) and viral recombinant antigens (Ags)
Competitive landscape
For the 4 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Defense, Dept of (DOD) or Office of the Secretary of Defense or Joint Chiefs of Staff since 2024 (1 filings)
- 0 of their lobbyists list a past Defense, Dept of (DOD) or Office of the Secretary of Defense or Joint Chiefs of Staff job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 1 bills named on the past winners' lobbying filings
- 32 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 1 of the past winners are listed companies
- 0 insider buys and 4 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.